A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma – the SKOPOS trial

A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma – the SKOPOS trial

Vaccines in combination with chemotherapy have been shown to be safe in different tumor types. We investigated the immunological activity of the TroVax® vaccine in combination with pemetrexed-cisplatin chemotherapy in malignant pleural mesothelioma (MPM). In this first line, open-label, single-arm,...

Full description

Bibliographic Details
Main Authors: Jason F Lester, Angela C Casbard, Saly Al-Taei, Richard Harrop, Lajos Katona, Richard L Attanoos, Zsuzsanna Tabi, Gareth O Griffiths
Format: Article
Language:English
Published: Taylor & Francis Group 2018-12-01
Series:OncoImmunology
Subjects:
mesothelioma
5t4 antigen
mva vaccine
t cell cytokines
immunophenotyping
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1457597

Internet

http://dx.doi.org/10.1080/2162402X.2018.1457597

Similar Items